Targeted Alpha Therapy

Unleashing the power of Alpha: Targeted alpha therapy (TAT) is an emerging class of cancer therapy delivering high-energy alpha radiation directly to the tumor inside the body. TAT is a potentially powerful new treatment modality and could give hope to patients suffering from life-threatening or difficult to treat cancers that are resistant to current treatment standards.

We have a long history in this field: Bayer was the first company to approve a targeted radionuclide therapy for prostate cancer patients in 2014, demonstrating its excellence in the global development, production and commercialization of this type of therapy. We believe that targeted alpha therapy has the potential to address the high unmet medical need across multiple cancer types. Our developing targeted alpha therapy portfolio includes novel targeting approaches where we combine alpha radionuclides with different targeting moieties, such as antibodies, peptides and small molecules intended for the use in multiple cancer indications. We have expertise along the entire value chain in developing these therapies and are committed to developing further TATs to help patients with difficult-to-treat tumors.